{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:08:50Z","timestamp":1790806130873,"version":"4.1.0"},"reference-count":41,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Von Hippel\u2013Lindau disease (VHL) is a hereditary disorder associated with malignant tumors including clear cell renal cell carcinoma (ccRCC). Partial nephrectomy is complicated by multilocular tumor occurrence and a high recurrence rate. The aim of this study was to evaluate the potential of stereotactic body radiotherapy (SBRT) as an alternative treatment approach in VHL patients with multiple ccRCC. Patients with VHL and a diagnosis of ccRCC were enrolled. SBRT was conducted using five fractions of 10 Gy or eight fractions of 7.5 Gy. The primary endpoint was local control (LC). Secondary endpoints included alteration of renal function and adverse events. Seven patients with a total of eight treated lesions were enrolled. Median age was 44 years. Five patients exhibited multiple bilateral kidney cysts in addition to ccRCC. Three patients underwent at least one partial nephrectomy in the past. After a median follow-up of 43 months, 2-year LC was 100%, while 2-year CSS, 2-year PFS and 2-year OS was 100%, 85.7% and 85.7%, respectively. SBRT was very well tolerated with no acute or chronic toxicities grade \u2265 2. Mean estimated glomerular filtration rate (eGFR) at baseline was 83.7 \u00b1 13.0 mL\/min\/1.73 m2, which decreased to 76.6 \u00b1 8.0 mL\/min\/1.73 m2 after 1 year. Although the sample size was small, SBRT resulted in an excellent LC rate and was very well tolerated with preservation of kidney function in patients with multiple renal lesions and cysts.<\/jats:p>","DOI":"10.3390\/cancers14205069","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T05:08:02Z","timestamp":1665983282000},"page":"5069","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel\u2013Lindau Disease\u2014Results of a Prospective Trial"],"prefix":"10.3390","volume":"14","author":[{"given":"Simon","family":"Kirste","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Medical Center\u2014University of Freiburg, Faculty of Medicine, 79106 Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (dkfz), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2022-897X","authenticated-orcid":false,"given":"Alexander","family":"R\u00fchle","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Medical Center\u2014University of Freiburg, Faculty of Medicine, 79106 Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (dkfz), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zschiedrich","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Internal Medicine, B\u00fcrgerspital Solothurn, 4500 Solothurn, Switzerland"},{"name":"Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schultze-Seemann","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical Center\u2014University of Freiburg, Faculty of Medicine, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula A.","family":"Jilg","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical Center\u2014University of Freiburg, Faculty of Medicine, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Neumann-Haefelin","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine, Medical Center\u2014University of Freiburg, Faculty of Medicine, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Medical Center\u2014University of Freiburg, Faculty of Medicine, 79106 Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (dkfz), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Medical Center\u2014University of Freiburg, Faculty of Medicine, 79106 Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (dkfz), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/332268a0","article-title":"Von Hippel\u2013Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma","volume":"332","author":"Seizinger","year":"1988","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/jmg.28.7.443","article-title":"Von Hippel-Lindau disease: A genetic study","volume":"28","author":"Maher","year":"1991","journal-title":"J. Med. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF01994821","article-title":"\u00dcber eine sehr seltene Erkrankung der Netzhaut","volume":"59","author":"Hippel","year":"1904","journal-title":"Albrecht Graefes Arch. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1755-3768.1926.tb07786.x","article-title":"Zur Frage der Angiomatosis retinae und ihrer Hirnkomplikationen","volume":"4","author":"Lindau","year":"1926","journal-title":"Acta Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15586\/jkcvhl.2017.88","article-title":"A Review of Von Hippel-Lindau Syndrome","volume":"4","author":"Varshney","year":"2017","journal-title":"J. Kidney Cancer VHL"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-444-62702-5.00010-X","article-title":"Von Hippel-Lindau disease","volume":"132","author":"Chittiboina","year":"2015","journal-title":"Handb. Clin. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"Von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-\u03b1 to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/0008-5472.CAN-09-2211","article-title":"NF-\u03baB\u2013Dependent Plasticity of the Epithelial to Mesenchymal Transition Induced by Von Hippel-Lindau Inactivation in Renal Cell Carcinomas","volume":"70","author":"Pantuck","year":"2010","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10689-012-9525-7","article-title":"Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up","volume":"11","author":"Jilg","year":"2012","journal-title":"Fam. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.eururo.2011.06.040","article-title":"Treatment of localised renal cell carcinoma","volume":"60","author":"Becker","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00330-018-5660-3","article-title":"Partial nephrectomy versus ablative techniques for small renal masses: A systematic review and network meta-analysis","volume":"29","author":"Uhlig","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.clgc.2017.07.027","article-title":"Radiofrequency Ablation for Renal Cancer in Von Hippel\u2013Lindau Syndrome Patients: A Prospective Cohort Analysis","volume":"16","author":"Allasia","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nrclinonc.2009.188","article-title":"Stereotactic body radiation therapy: A novel treatment modality","volume":"7","author":"Lo","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_17","first-page":"104","article-title":"Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?","volume":"18","author":"Andratschke","year":"2019","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrurol.2017.87","article-title":"Radiotherapy for renal cell carcinoma: Renaissance of an overlooked approach","volume":"14","author":"Siva","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.juro.2009.05.035","article-title":"The Renal nephrometry score: A comprehensive standardized system for quantitating renal tumor size, location and depth","volume":"182","author":"Kutikov","year":"2009","journal-title":"J. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/00365598709180784","article-title":"A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma: A study by the Copenhagen Renal Cancer Study Group","volume":"21","author":"Kjaer","year":"1987","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/00365597709179965","article-title":"Preoperative Irradiation in the Treatment of Renal Adenocarcinoma","volume":"11","author":"Juusela","year":"1977","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ali, M., Mooi, J., Lawrentschuk, N., McKay, R.R., Hannan, R., Lo, S.S., Hall, W.A., and Siva, S. (2022). The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. Eur. Urol.","DOI":"10.1016\/j.eururo.2022.08.018"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2020.10.031","article-title":"Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma","volume":"155","author":"Grubb","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clon.2021.03.002","article-title":"Patient-reported quality of life following stereotactic body radiation therapy for primary kidney cancer\u2013results from a prospective cohort study","volume":"33","author":"Swaminath","year":"2021","journal-title":"Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ijrobp.2021.01.054","article-title":"Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus\u2014Safety Lead-in Results of a Phase 2 Trial","volume":"110","author":"Margulis","year":"2021","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.radonc.2016.01.027","article-title":"Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose\u2013response relationship","volume":"118","author":"Siva","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.13811","article-title":"Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: A prospective clinical trial","volume":"120","author":"Siva","year":"2017","journal-title":"Br. J. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of Renal Cell Carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","article-title":"von Hippel\u2013Lindau disease: A clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0022-5347(01)66674-6","article-title":"Prevalence of Microscopic lesions in Grossly Normal Renal Parenchyma from Patients with von Hippel-Lindau Disease, Sporadic Renal Cell Carcinoma and No Renal Disease","volume":"154","author":"Walther","year":"1995","journal-title":"J. Urol."},{"key":"ref_33","first-page":"686","article-title":"Probe ablation as salvage therapy for renal tumors in von Hippel-Lindau patients: The Cleveland Clinic experience with 3 years follow-up","volume":"31","author":"Yang","year":"2013","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.juro.2010.01.022","article-title":"Percutaneous radio frequency ablation of renal tumors in patients with von Hippel-Lindau disease: Preliminary results","volume":"183","author":"Park","year":"2010","journal-title":"J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.clgc.2022.03.011","article-title":"Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC)","volume":"20","author":"Donovan","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.juro.2014.08.044","article-title":"Single Fraction Radiosurgery for the Treatment of Renal Tumors","volume":"193","author":"Staehler","year":"2015","journal-title":"J. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.31156","article-title":"Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"124","author":"Siva","year":"2018","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Siva, S., Chesson, B., Bressel, M., Pryor, D., Higgs, B., Reynolds, H.M., Hardcastle, N., Montgomery, R., Vanneste, B., and Khoo, V. (2018). TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney\u2014FASTRACK II. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4916-2"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2214\/AJR.14.14099","article-title":"Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal Tumors","volume":"206","author":"Sun","year":"2016","journal-title":"Am. J. Roentgenol."},{"key":"ref_40","first-page":"e1799","article-title":"First Ever Use of Proton Stereotactic Body Radiation Therapy Delivered with Curative Intent to Bilateral Synchronous Primary Renal Cell Carcinomas","volume":"9","author":"Frick","year":"2017","journal-title":"Cureus"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1080\/02841860802123196","article-title":"Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney","volume":"47","author":"Svedman","year":"2008","journal-title":"Acta Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/5069\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:55:27Z","timestamp":1760144127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/5069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":41,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14205069"],"URL":"https:\/\/doi.org\/10.3390\/cancers14205069","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]}}}